Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 129 articles:
HTML format
Text format



Single Articles


    December 2016
  1. LANGE AP, Lima AS, Lucena-Araujo AR, Jacomo RH, et al
    The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.
    Br J Haematol. 2016 Dec 26. doi: 10.1111/bjh.14490.
    PubMed     Text format    


    July 2016
  2. DANILOV AV, Lewis LD, Lansigan F, Roudaia L, et al
    A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
    Br J Haematol. 2016 Jul 5. doi: 10.1111/bjh.14171.
    PubMed     Text format    


    April 2016
  3. VAN DYKE DL, Werner L, Rassenti LZ, Neuberg D, et al
    The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.
    Br J Haematol. 2016;173:105-13.
    PubMed     Text format     Abstract available


  4. DAVIS Z, Forconi F, Parker A, Gardiner A, et al
    The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity.
    Br J Haematol. 2016;173:127-36.
    PubMed     Text format     Abstract available


  5. JAIN P, Kantarjian H, Sasaki K, Jabbour E, et al
    Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
    Br J Haematol. 2016;173:114-26.
    PubMed     Text format     Abstract available


  6. BALLEN KK, Lazarus H
    Cord blood transplant for acute myeloid leukaemia.
    Br J Haematol. 2016;173:25-36.
    PubMed     Text format     Abstract available


  7. JACKSON RK, Irving JA, Veal GJ
    Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:13-24.
    PubMed     Text format     Abstract available


  8. JIANG X, Zhang L, Zhou D
    Acute promyelocytic leukaemia with promyelocyte count below 20.
    Br J Haematol. 2016;173:11.
    PubMed     Text format    


  9. RIDER TG, Grace RJ, Newman JA
    Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.
    Br J Haematol. 2016;173:326-7.
    PubMed     Text format    


  10. DANILOV AV
    Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.
    Br J Haematol. 2016;173:327-8.
    PubMed     Text format    


  11. LOPEZ C, Bergmann AK, Paul U, Murga Penas EM, et al
    Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
    Br J Haematol. 2016;173:265-73.
    PubMed     Text format     Abstract available


  12. ABRAHAO R, Keogh RH, Lichtensztajn DY, Marcos-Gragera R, et al
    Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study.
    Br J Haematol. 2016;173:292-302.
    PubMed     Text format     Abstract available


  13. KERSTEN B, Valkering M, Wouters R, van Amerongen R, et al
    CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia.
    Br J Haematol. 2016;173:219-35.
    PubMed     Text format     Abstract available


  14. MELO CP, Campos CB, Rodrigues Jde O, Aguirre-Neto JC, et al
    Long non-coding RNAs: biomarkers for acute leukaemia subtypes.
    Br J Haematol. 2016;173:318-20.
    PubMed     Text format    


  15. MCGEHEE E, Rakheja D, Oliver D, Chen W, et al
    The importance of plasma D-2HG measurement in screening for IDH mutations in acute myeloid leukaemia.
    Br J Haematol. 2016;173:323-6.
    PubMed     Text format    


  16. GLANCY E, Siles R
    Monoclonal B-cell lymphocytosis and hypogammaglobulinaemia.
    Br J Haematol. 2016;173:316-7.
    PubMed     Text format    


    March 2016
  17. GUO RJ, Bahmanyar M, Minden MD, Chang H, et al
    CD33, not early precursor T-cell phenotype, is associated with adverse outcome in adult T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:823-5.
    PubMed     Text format    


  18. VAN DER VELDEN VH, de Launaij D, de Vries JF, de Haas V, et al
    New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:769-81.
    PubMed     Text format     Abstract available


  19. IRVING JA
    Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:655-66.
    PubMed     Text format     Abstract available


  20. FERNANDES CM, Hamerschlak N, Kishimoto RK, Ratis CA, et al
    Radiotherapy-related acute myeloid leukaemia with KMT2A amplification.
    Br J Haematol. 2016;172:653.
    PubMed     Text format    


  21. HOFBAUER SW, Krenn PW, Pinomicronn Hofbauer J, Pucher S, et al
    The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2016;172:815-9.
    PubMed     Text format    


  22. BERQUET L, Valleron W, Grgurevic S, Quelen C, et al
    Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia.
    Br J Haematol. 2016;172:819-23.
    PubMed     Text format    


  23. MAIQUES-DIAZ A, Hernando M, Sanchez-Lopez A, Rio-Machin A, et al
    MAPK8-mediated stabilization of SP1 is essential for RUNX1-RUNX1T1 - driven leukaemia.
    Br J Haematol. 2016;172:807-10.
    PubMed     Text format    


  24. BLECKMANN K, Schrappe M
    Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.
    Br J Haematol. 2016;172:855-69.
    PubMed     Text format     Abstract available


  25. MIDDEKE JM, Herold S, Rucker-Braun E, Berdel WE, et al
    TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2016;172:914-22.
    PubMed     Text format     Abstract available


  26. HINAI AA, Valk PJ
    Review: Aberrant EVI1 expression in acute myeloid leukaemia.
    Br J Haematol. 2016;172:870-8.
    PubMed     Text format     Abstract available


  27. MUNOZ-BALLESTER J, Chen-Liang TH, Hurtado AM, Heras I, et al
    Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations.
    Br J Haematol. 2016;172:937-46.
    PubMed     Text format     Abstract available


  28. IACCARINO L, Ottone T, Divona M, Cicconi L, et al
    Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
    Br J Haematol. 2016;172:909-13.
    PubMed     Text format     Abstract available


  29. LO-COCO F, Cicconi L, Breccia M
    Current standard treatment of adult acute promyelocytic leukaemia.
    Br J Haematol. 2016;172:841-54.
    PubMed     Text format     Abstract available


  30. WANG HY, McMahon C, Ali SM, Young LE, et al
    Novel FNDC3B and MECOM fusion and WT1 L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia.
    Br J Haematol. 2016;172:987-90.
    PubMed     Text format    


  31. VIOLA S, Traer E, Huan J, Hornick NI, et al
    Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.
    Br J Haematol. 2016;172:983-6.
    PubMed     Text format    


    February 2016
  32. CHANG JE, Havighurst T, Kim K, Eickhoff J, et al
    Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13957.
    PubMed     Text format     Abstract available


  33. HOUGH R, Rowntree C, Goulden N, Mitchell C, et al
    Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
    Br J Haematol. 2016;172:439-51.
    PubMed     Text format     Abstract available


  34. DEL GIUDICE I, Marinelli M, Wang J, Bonina S, et al
    Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.
    Br J Haematol. 2016;172:371-83.
    PubMed     Text format     Abstract available


  35. NIAVARANI A, Herold T, Reyal Y, Sauerland MC, et al
    A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2016;172:401-11.
    PubMed     Text format     Abstract available


  36. KURTOVIC-KOZARIC A, Hasic A, Radich JP, Bijedic V, et al
    The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients.
    Br J Haematol. 2016;172:420-7.
    PubMed     Text format     Abstract available


  37. RAVANDI F, Jorgensen JL, O'Brien SM, Jabbour E, et al
    Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:392-400.
    PubMed     Text format     Abstract available


  38. DE BRAEKELEER M, Gueganic N, Tous C, Le Bris MJ, et al
    Translocations involving 13q14 without associated deletion in chronic lymphoid leukaemia target DLEU2.
    Br J Haematol. 2016;172:467-9.
    PubMed     Text format    


  39. DICKSON GJ, Bustraan S, Hills RK, Ali A, et al
    The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.
    Br J Haematol. 2016;172:573-80.
    PubMed     Text format     Abstract available


  40. AL MALKI MM, Song JY
    Strongyloides hyperinfection syndrome following haematopoietic stem cell transplantation.
    Br J Haematol. 2016;172:496.
    PubMed     Text format    


  41. DEVILLIER R, Raffoux E, Rey J, Lengline E, et al
    Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
    Br J Haematol. 2016;172:628-30.
    PubMed     Text format    


    January 2016
  42. MAWAD R, Becker PS, Hendrie P, Scott B, et al
    Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Br J Haematol. 2016;172:238-45.
    PubMed     Text format     Abstract available


  43. ELSE M, Wade R, Oscier D, Catovsky D, et al
    The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
    Br J Haematol. 2016;172:228-37.
    PubMed     Text format     Abstract available


  44. MACCHIA G, Lonoce A, Venuto S, Macri E, et al
    A rare but recurrent t(8;13)(q24;q14) translocation in B-cell chronic lymphocytic leukaemia causing MYC up-regulation and concomitant loss of PVT1, miR-15/16 and DLEU7.
    Br J Haematol. 2016;172:296-9.
    PubMed     Text format    


  45. BAUMANN T, Delgado J, Santacruz R, Martinez-Trillos A, et al
    CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
    Br J Haematol. 2016;172:48-55.
    PubMed     Text format     Abstract available


  46. BRUMMENDORF TH, Cortes JE, Khoury HJ, Kantarjian HM, et al
    Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
    Br J Haematol. 2016;172:97-110.
    PubMed     Text format     Abstract available


  47. LOEB KR, Cherian S, Becker PS, Walter RB, et al
    Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid.
    Br J Haematol. 2016;172:134-6.
    PubMed     Text format    


  48. APOLLONIO B, Ramsay AG
    Subclonal heterogeneity in chronic lymphocytic leukaemia: revealing the importance of the lymphoid tumour microenvironment.
    Br J Haematol. 2016;172:7-8.
    PubMed     Text format    


    December 2015
  49. SHIBA N, Ohki K, Kobayashi T, Hara Y, et al
    High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
    Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13869.
    PubMed     Text format     Abstract available


  50. CHIHARA D, Cheah CY, Westin JR, Fayad LE, et al
    Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
    Br J Haematol. 2015 Dec 9. doi: 10.1111/bjh.13796.
    PubMed     Text format     Abstract available


    November 2015
  51. PREBET T, Sun Z, Ketterling RP, Zeidan A, et al
    Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
    Br J Haematol. 2015 Nov 18. doi: 10.1111/bjh.13832.
    PubMed     Text format     Abstract available


  52. BAIN BJ, Ahmad S
    Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions.
    Br J Haematol. 2015;171:400-10.
    PubMed     Text format     Abstract available


  53. LOKIREDDY P, Bloxam D, Hodson A, Whalley I, et al
    Extramedullary acute myeloid leukaemia: isolated leukaemic pleural and pericardial effusions without marrow disease.
    Br J Haematol. 2015;171:295.
    PubMed     Text format    


  54. ZHONG H, Chen G, Jukofsky L, Geho D, et al
    MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
    Br J Haematol. 2015;171:432-5.
    PubMed     Text format    


  55. DINMOHAMED AG, Brink M, Visser O, Sonneveld P, et al
    Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012.
    Br J Haematol. 2015;171:436-9.
    PubMed     Text format    


    October 2015
  56. AWASTHI A, Ayello J, Van de Ven C, Elmacken M, et al
    Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20 rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukae
    Br J Haematol. 2015 Oct 16. doi: 10.1111/bjh.13764.
    PubMed     Text format     Abstract available


  57. WATTS JM, Kishtagari A, Hsu M, Lacouture ME, et al
    Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center.
    Br J Haematol. 2015;171:84-90.
    PubMed     Text format     Abstract available


  58. VAN LAAR M, Kinsey SE, Feltbower RG
    Survival of childhood acute lymphoid leukaemia in Yorkshire by clinical trial era, 1990-2011.
    Br J Haematol. 2015;171:116-9.
    PubMed     Text format     Abstract available


  59. TANAKA Y, Kato M, Hasegawa D, Urayama KY, et al
    Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.
    Br J Haematol. 2015;171:109-15.
    PubMed     Text format     Abstract available


  60. DI GIACOMO D, La Starza R, Barba G, Pierini V, et al
    4q12 translocations with GSX2 expression identify a CD7(+) acute myeloid leukaemia subset.
    Br J Haematol. 2015;171:141-5.
    PubMed     Text format    


    September 2015
  61. WANG W, Xie W, Hu S
    Cup-like blasts in B-lymphoblastic leukaemia.
    Br J Haematol. 2015;170:596.
    PubMed     Text format    


  62. DAVIDS MS, Vartanov A, Werner L, Neuberg D, et al
    Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort.
    Br J Haematol. 2015;170:694-703.
    PubMed     Text format     Abstract available


  63. LONG X, Yu Y, Perlaky L, Man TK, et al
    Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.
    Br J Haematol. 2015;170:704-18.
    PubMed     Text format     Abstract available


  64. LAUSEKER M, Schemenau J, Strupp C, Kundgen A, et al
    In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
    Br J Haematol. 2015;170:687-93.
    PubMed     Text format     Abstract available


  65. ROBERTS AW, Advani RH, Kahl BS, Persky D, et al
    Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
    Br J Haematol. 2015;170:669-78.
    PubMed     Text format     Abstract available


  66. MANDA S, Dunbar N, Marx-Wood CR, Danilov AV, et al
    Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
    Br J Haematol. 2015;170:734-6.
    PubMed     Text format    


  67. DOCHERTY SM, Reza M, Turner G, Bowles K, et al
    Resolution of Roth spots in chronic myeloid leukaemia after treatment with imatinib.
    Br J Haematol. 2015;170:744.
    PubMed     Text format    


  68. OLSSON L, Ivanov Ofverholm I, Noren-Nystrom U, Zachariadis V, et al
    The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 19
    Br J Haematol. 2015;170:847-58.
    PubMed     Text format     Abstract available


    August 2015
  69. YAMAMOTO H, Yamamoto M, Omoto E, Kato T, et al
    An isolated myeloid blast crisis presenting as optic nerve sarcoma in a patient with chronic myeloid leukaemia treated with imatinib.
    Br J Haematol. 2015;170:290.
    PubMed     Text format    


  70. KHAN AA, Harrison CN, McLornan DP
    Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?
    Br J Haematol. 2015;170:323-35.
    PubMed     Text format     Abstract available


  71. FALINI B, Sportoletti P, Brunetti L, Martelli MP, et al
    Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
    Br J Haematol. 2015;170:305-22.
    PubMed     Text format     Abstract available


  72. GIONA F, Putti MC, Micalizzi C, Menna G, et al
    Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.
    Br J Haematol. 2015;170:398-407.
    PubMed     Text format     Abstract available


  73. SANO H, Ohki K, Park MJ, Shiba N, et al
    CSF3R and CALR mutations in paediatric myeloid disorders and the association of CSF3R mutations with translocations, including t(8; 21).
    Br J Haematol. 2015;170:391-7.
    PubMed     Text format     Abstract available


  74. BUCKLEY SA, Mawad R, Gooley TA, Becker PS, et al
    A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
    Br J Haematol. 2015;170:349-55.
    PubMed     Text format     Abstract available


  75. PAGANO L, Stamouli M, Tumbarello M, Verga L, et al
    Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry.
    Br J Haematol. 2015;170:434-9.
    PubMed     Text format    


  76. MCGREGOR AK, Das-Gupta E
    Acute myeloid leukaemia in pregnancy.
    Br J Haematol. 2015;170:441-2.
    PubMed     Text format    


  77. ALI S, Jones GL, Culligan DJ, Marsden PJ, et al
    Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy.
    Br J Haematol. 2015;170:487-95.
    PubMed     Text format     Abstract available


  78. PEARSON-STUTTARD B, Soutar R, Leach M
    Acute kidney injury from tumour lysis syndrome and urate crystalluria.
    Br J Haematol. 2015;170:444.
    PubMed     Text format    


  79. LENNARD L, Cartwright CS, Wade R, Vora A, et al
    Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003.
    Br J Haematol. 2015;170:550-8.
    PubMed     Text format     Abstract available


  80. GASSNER FJ, Zaborsky N, Catakovic K, Rebhandl S, et al
    Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
    Br J Haematol. 2015;170:515-22.
    PubMed     Text format     Abstract available


  81. LEHMBERG K, Sprekels B, Nichols KE, Woessmann W, et al
    Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents.
    Br J Haematol. 2015;170:539-49.
    PubMed     Text format     Abstract available


  82. KADIA T, Kantarjian H, Garcia-Manero G, Borthakur G, et al
    Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.
    Br J Haematol. 2015;170:590-3.
    PubMed     Text format    


    July 2015
  83. YIN T, Burthem J, McAlpine A, Telford N, et al
    Erythrophagocytosis of myeloblasts in acute myeloid leukaemia exhibiting chromosome 8p abnormality and extramedullary disease.
    Br J Haematol. 2015;170:139.
    PubMed     Text format    


  84. MILLER CR, Stephens D, Ruppert AS, Racke F, et al
    Jumping translocations, a novel finding in chronic lymphocytic leukaemia.
    Br J Haematol. 2015;170:200-7.
    PubMed     Text format     Abstract available


  85. SELLAR RS, Fend F, Akarca AU, Agostinelli C, et al
    BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients.
    Br J Haematol. 2015;170:282-5.
    PubMed     Text format    


  86. DANILOVA OV, Paiva C, Kaur P, Kamal A, et al
    MIR21 is differentially expressed in the lymphoid tissue and modulated by stromal signalling in chronic lymphocytic leukaemia.
    Br J Haematol. 2015;170:272-5.
    PubMed     Text format    


  87. EMERENCIANO M, Barbosa Tda C, de Almeida Lopes B, Meyer C, et al
    Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia.
    Br J Haematol. 2015;170:268-71.
    PubMed     Text format    


  88. MANGLA A, Mushtaq MU, Catchatourian R
    Aleukaemic leukaemia cutis.
    Br J Haematol. 2015;170:4.
    PubMed     Text format    


  89. KHAN N, Freeman SD, Virgo P, Couzens S, et al
    An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.
    Br J Haematol. 2015;170:80-4.
    PubMed     Text format     Abstract available


  90. PHILIP C, George B, Ganapule A, Korula A, et al
    Acute myeloid leukaemia: challenges and real world data from India.
    Br J Haematol. 2015;170:110-7.
    PubMed     Text format     Abstract available


  91. HOKLAND P, Cotter F
    Real world data on acute myeloid leukaemia therapy from the developing world--an eye-opener.
    Br J Haematol. 2015;170:1-2.
    PubMed     Text format    


  92. OSTERBORG A, Wierda WG, Mayer J, Hess G, et al
    Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
    Br J Haematol. 2015;170:40-9.
    PubMed     Text format     Abstract available


  93. GANZEL C, Devlin S, Douer D, Rowe JM, et al
    Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy.
    Br J Haematol. 2015;170:50-5.
    PubMed     Text format     Abstract available


  94. THOMPSON PA, Ferrajoli A, O'Brien S, Wierda WG, et al
    Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2015;170:125-8.
    PubMed     Text format    


    June 2015
  95. MILLOT F, Suttorp M
    Managing children with chronic myeloid leukaemia--response to Baccarani.
    Br J Haematol. 2015;169:760-1.
    PubMed     Text format    


  96. BACCARANI M
    Managing children with chronic myeloid leukaemia.
    Br J Haematol. 2015;169:759-60.
    PubMed     Text format    


  97. OHTA S, Najima Y, Imamura J
    Dasatinib-induced gastric antral vascular ectasia in a patient with acute lymphoblastic leukaemia.
    Br J Haematol. 2015;169:612.
    PubMed     Text format    


  98. SANDAHL JD, Kjeldsen E, Abrahamsson J, Ha SY, et al
    The applicability of the WHO classification in paediatric AML. A NOPHO-AML study.
    Br J Haematol. 2015;169:859-67.
    PubMed     Text format     Abstract available


  99. FIEDLER W, Kayser S, Kebenko M, Janning M, et al
    A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
    Br J Haematol. 2015;169:694-700.
    PubMed     Text format     Abstract available


  100. GUNNARSSON N, Stenke L, Hoglund M, Sandin F, et al
    Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
    Br J Haematol. 2015;169:683-8.
    PubMed     Text format     Abstract available


  101. HERNANDEZ-CABALLERO A, Arellano-Llamas AA, Cruz-Rico J, Ojeda JV, et al
    Genetic susceptibility variants for chronic lymphocytic leukaemia in Mexican mestizos.
    Br J Haematol. 2015;169:909-11.
    PubMed     Text format    


  102. OSHIKAWA G, Kakihana K, Saito M, Aoki J, et al
    Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
    Br J Haematol. 2015;169:756-9.
    PubMed     Text format    


    May 2015
  103. OLSSON L, Johansson B
    Ikaros and leukaemia.
    Br J Haematol. 2015;169:479-91.
    PubMed     Text format     Abstract available


  104. HANSEN MC, Nyvold CG, Roug AS, Kjeldsen E, et al
    Nature and nurture: a case of transcending haematological pre-malignancies in a pair of monozygotic twins adding possible clues on the pathogenesis of B-cell proliferations.
    Br J Haematol. 2015;169:391-400.
    PubMed     Text format     Abstract available


  105. SWORDS RT, Erba HP, DeAngelo DJ, Bixby DL, et al
    Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
    Br J Haematol. 2015;169:534-43.
    PubMed     Text format     Abstract available


  106. UCKUN FM, Ma H, Cheng J, Myers DE, et al
    CD22DeltaE12 as a molecular target for RNAi therapy.
    Br J Haematol. 2015;169:401-14.
    PubMed     Text format     Abstract available


  107. ESTECIO MR, Maddipoti S, Bueso-Ramos C, DiNardo CD, et al
    RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
    Br J Haematol. 2015;169:344-51.
    PubMed     Text format     Abstract available


  108. OHANIAN M, Rozovski U, Ravandi F, Garcia-Manero G, et al
    Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia.
    Br J Haematol. 2015;169:595-7.
    PubMed     Text format    


  109. BLOOR A, De Cock E, Hatswell AJ, Wasiak R, et al
    Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL).
    Br J Haematol. 2015;169:449-52.
    PubMed     Text format    


  110. DANESHMANESH AH, Hojjat-Farsangi M, Moshfegh A, Khan AS, et al
    The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.
    Br J Haematol. 2015;169:455-8.
    PubMed     Text format    


  111. OJHA J, Secreto CR, Rabe KG, Van Dyke DL, et al
    Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia.
    Br J Haematol. 2015;169:445-8.
    PubMed     Text format    


    April 2015
  112. ZHANG SQ, Smith SM, Zhang SY, Lynn Wang Y, et al
    Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2015 Apr 9. doi: 10.1111/bjh.13427.
    PubMed     Text format     Abstract available


  113. STREFFORD JC
    The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications.
    Br J Haematol. 2015;169:14-31.
    PubMed     Text format     Abstract available


  114. SCHUSTER FR, Stanglmaier M, Woessmann W, Winkler B, et al
    Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
    Br J Haematol. 2015;169:90-102.
    PubMed     Text format     Abstract available


  115. MOLICA M, Zacheo I, Diverio D, Alimena G, et al
    Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline.
    Br J Haematol. 2015;169:148-50.
    PubMed     Text format    


  116. LIANG Y, Yang LH, Jiang H, Yuan XJ, et al
    Treatment outcome of young children with acute lymphoblastic leukaemia: achievements and directions implied from Shanghai Children's Medical Centre based SCMC-ALL-2005 protocol.
    Br J Haematol. 2015;169:267-77.
    PubMed     Text format     Abstract available


  117. WEI A, Tan P, Perruzza S, Govindaraj C, et al
    Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
    Br J Haematol. 2015;169:199-210.
    PubMed     Text format     Abstract available


  118. MARQUEZ ME, Hernandez-Uzcategui O, Cornejo A, Vargas P, et al
    Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
    Br J Haematol. 2015;169:211-8.
    PubMed     Text format     Abstract available


  119. POCHON C, Oger E, Michel G, Dalle JH, et al
    Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.
    Br J Haematol. 2015;169:249-61.
    PubMed     Text format     Abstract available


  120. LENNARD L, Cartwright CS, Wade R, Vora A, et al
    Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
    Br J Haematol. 2015;169:228-40.
    PubMed     Text format     Abstract available


  121. HUTTERER E, Asslaber D, Caldana C, Krenn PW, et al
    CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms.
    Br J Haematol. 2015;169:286-9.
    PubMed     Text format    


    March 2015
  122. ISHIDA T, Jo T, Takemoto S, Suzushima H, et al
    Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
    Br J Haematol. 2015 Mar 2. doi: 10.1111/bjh.13338.
    PubMed     Text format     Abstract available


  123. ABLA O, Stimec J, Abdelhaleem M, Howard A, et al
    Paediatric acute lymphoblastic leukaemia mimicking Langerhans cell histiocytosis of bone.
    Br J Haematol. 2015;168:770.
    PubMed     Text format    


  124. STUART RK, Cripe LD, Maris MB, Cooper MA, et al
    REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
    Br J Haematol. 2015;168:796-805.
    PubMed     Text format     Abstract available


  125. HERBAUX C, Genet P, Bouabdallah K, Pignon JM, et al
    Bendamustine is effective in T-cell prolymphocytic leukaemia.
    Br J Haematol. 2015;168:916-9.
    PubMed     Text format    


  126. LI J, Zhong HY, Zhang Y, Xiao L, et al
    GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid.
    Br J Haematol. 2015;168:904-8.
    PubMed     Text format    


    January 2015
  127. SUEHIRO Y, Hasegawa A, Iino T, Sasada A, et al
    Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study.
    Br J Haematol. 2015 Jan 22. doi: 10.1111/bjh.13302.
    PubMed     Text format     Abstract available


    December 2014
  128. TUCUNDUVA L, Volt F, Cunha R, Locatelli F, et al
    Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases.
    Br J Haematol. 2014 Dec 18. doi: 10.1111/bjh.13267.
    PubMed     Text format     Abstract available


    October 2014
  129. CHEMINANT M, Bruneau J, Kosmider O, Lefrere F, et al
    Efficacy of 5-Azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma.
    Br J Haematol. 2014 Oct 14. doi: 10.1111/bjh.13170.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: